Log In
Print
BCIQ
Print
Print this Print this
 

ATI355

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionMAb that inhibits NOGO
Molecular Target Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSpinal cord injury (SCI)
Indication DetailsTreat acute spinal cord injury (SCI)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today